1. Home
  2. ENTA vs BVS Comparison

ENTA vs BVS Comparison

Compare ENTA & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.96

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Logo Bioventus Inc.

BVS

Bioventus Inc.

HOLD

Current Price

$8.66

Market Cap

482.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
BVS
Founded
1995
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.3M
482.9M
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
ENTA
BVS
Price
$12.96
$8.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$20.40
$14.25
AVG Volume (30 Days)
155.3K
306.1K
Earning Date
01-01-0001
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
163.46
EPS
N/A
0.33
Revenue
$102,814,000.00
$568,087,000.00
Revenue This Year
$5.91
$7.42
Revenue Next Year
N/A
$6.46
P/E Ratio
N/A
$26.06
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$5.81
52 Week High
$17.15
$10.13

Technical Indicators

Market Signals
Indicator
ENTA
BVS
Relative Strength Index (RSI) 41.06 52.81
Support Level $12.09 $6.42
Resistance Level $15.52 $9.01
Average True Range (ATR) 0.81 0.39
MACD -0.15 -0.03
Stochastic Oscillator 4.86 34.81

Price Performance

Historical Comparison
ENTA
BVS

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Share on Social Networks: